Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses

Kennosuke Karube, Masao Nakagawa, Shinobu Tsuzuki, Ichiro Takeuchi, Keiichiro Honma, Yasuhiro Nakashima, Norio Shimizu, Young-Hyeh Ko, Yasuo Morishima, Koichi Ohshima, Shigeo Nakamura, Masao Seto

Blood (2011) 118 (12): 3195–3204.

https://doi.org/10.1182/blood-2011-04-346890

Published: 2011

Includes: Supplemental data

Journal Articles

TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas

Keiichiro Honma, Shinobu Tsuzuki, Masao Nakagawa, Hiroyuki Tagawa, Shigeo Nakamura, Yasuo Morishima, Masao Seto

Blood (2009) 114 (12): 2467–2475.

https://doi.org/10.1182/blood-2008-12-194852

Published: 2009

Includes: Supplemental data

Journal Articles

Ocular Adnexal Marginal Zone B Cell Lymphoma Has Characteristic Deletion at Chromosome Band 6q23.3-24.1 Whose Target Is TNFAIP3 .

Keiichiro Honma, MD, Shinobu Tsuzuki, MD, PhD, Masao Nakagawa, MD, PhD, Sivasundaram Karnan, MS, Won-Seog Kim, MD, Yoon-Duk Kim, MD, Young-Hyeh Ko, MD, Masao Seto, MD, PhD

Blood (2007) 110 (11): 2643.

https://doi.org/10.1182/blood.V110.11.2643.2643

Published: 2007

Journal Articles

A Phase II Clinical Study of Rituximab and High-Dose Biweekly THP-COP (Pirarubicin, Cyclophosphamide, Vincristine and Predonisolone) with G-CSF for Non-Hodgkin Lymphoma: Results of a Multicentric Study of NMLSG (Niigata Malignant Lymphoma Study Group).

Jun Takizawa, MD, PhD, Sadao Aoki, MD, PhD, Kazue Takai, MD, Tohri Kurasaki, MD, Keiichiro Honma, MD, Masutaka Higashimura, MD, Kouichi Nagai, MD, Akihito Momoi, MD, PhD, Koji Nikkuni, MD, PhD, Yoshufusa Aizawa, MD

Blood (2005) 106 (11): 4734.

https://doi.org/10.1182/blood.V106.11.4734.4734

Published: 2005

Journal Articles

The Useful Individualized Assessment of Immunosuppressive Therapy with Cyclosporine A (CsA) after Allogeneic Stem Cell Transplantation by Simultaneous Analyses of Cytokine Production among CD4+ T Cells and Blood CsA Levels.

Nobuhiro Tsukada, MD, PhD, Tatsuo Furukawa, MD, PhD, Hiromi Ito, Noriko Izumi, MD, Akihito Momoi, MD, Kiyoshi Okazuka, MD, Keiichiro Honma, MD, Masayoshi Masuko, MD, PhD, Shigeo Hashimoto, MD, PhD, Sadao Aoki, MD, PhD, Yoshifusa Aizawa, MD, PhD

Blood (2004) 104 (11): 5076.

https://doi.org/10.1182/blood.V104.11.5076.5076

Published: 2004

NARROW

Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses

TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas

Ocular Adnexal Marginal Zone B Cell Lymphoma Has Characteristic Deletion at Chromosome Band 6q23.3-24.1 Whose Target Is TNFAIP3 .

A Phase II Clinical Study of Rituximab and High-Dose Biweekly THP-COP (Pirarubicin, Cyclophosphamide, Vincristine and Predonisolone) with G-CSF for Non-Hodgkin Lymphoma: Results of a Multicentric Study of NMLSG (Niigata Malignant Lymphoma Study Group).

The Useful Individualized Assessment of Immunosuppressive Therapy with Cyclosporine A (CsA) after Allogeneic Stem Cell Transplantation by Simultaneous Analyses of Cytokine Production among CD4+ T Cells and Blood CsA Levels.

Email alerts

ASH Publications

American Society of Hematology

Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses

TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas

Ocular Adnexal Marginal Zone B Cell Lymphoma Has Characteristic Deletion at Chromosome Band 6q23.3-24.1 Whose Target Is TNFAIP3 .

A Phase II Clinical Study of Rituximab and High-Dose Biweekly THP-COP (Pirarubicin, Cyclophosphamide, Vincristine and Predonisolone) with G-CSF for Non-Hodgkin Lymphoma: Results of a Multicentric Study of NMLSG (Niigata Malignant Lymphoma Study Group).

The Useful Individualized Assessment of Immunosuppressive Therapy with Cyclosporine A (CsA) after Allogeneic Stem Cell Transplantation by Simultaneous Analyses of Cytokine Production among CD4+ T Cells and Blood CsA Levels.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only